C

    Cardiff Oncology Inc (CRDF)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.99
    +0.05 (+5.70%)

    Market Cap: $73.13M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    +5.87%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.14 - $-0.13
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    5
    30d
    EPS Estimate Drift
    90d ago$-0.13+2.2%
    60d ago$-0.17-24.7%
    30d ago$-0.17-24.7%
    7d ago$-0.17-24.7%
    Current$-0.14
    Revenue Consensus
    $17000
    Range$0 - $50000
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.14
    Range$-0.18 - $-0.08
    5 analysts
    Revenue Consensus
    $100640
    Range$-59500 - $280500
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.14---
    Sep 26EST
    		-$-0.14---
    Jun 26
    		$-0.14$-0.17+17.65%Beat+33.3%
    Mar 26
    		$-0.18$-0.12-50.00%Miss+10.0%
    Dec 25
    		$-0.11$-0.20+45.00%Beat+47.6%
    Sep 25
    		$-0.17$-0.21+19.05%Beat+32.0%
    Jun 25
    		$-0.21$-0.20-5.00%Miss+19.2%
    Mar 25
    		$-0.20$-0.19-5.26%Miss+9.1%
    Dec 24
    		$-0.21$-0.25+15.15%Beat+0.0%
    Sep 24
    		$-0.25$-0.27+7.41%Beat-13.6%
    Jun 24
    		$-0.26$-0.25-4.00%Miss-4.0%
    Mar 24
    		$-0.22$-0.25+12.00%Beat+12.0%
    Dec 23
    		$-0.21$-0.28+25.00%Beat-5.0%
    Sep 23
    		$-0.22$-0.29+24.14%Beat-10.0%
    Jun 23
    		$-0.25$-0.25+0.00%Beat-4.2%
    Mar 23
    		$-0.25$-0.22-13.64%Miss+0.0%
    Dec 22
    		$-0.20$-0.23+13.04%Beat+13.0%
    Sep 22
    		$-0.20$-0.24+16.67%Beat-17.6%
    Jun 22
    		$-0.24$-0.25+4.00%Beat-41.2%
    Mar 22
    		$-0.25$-0.23-8.70%Miss-78.6%
    Dec 21
    		$-0.23$-0.17-35.29%Miss-187.5%
    Sep 21
    		$-0.17$-0.17+0.00%Beat+10.5%
    Jun 21
    		$-0.17$-0.15-13.33%Miss+66.7%
    Mar 21
    		$-0.14$-0.15+6.67%Beat+65.9%
    Dec 20
    		$-0.08$-0.14+42.86%Beat+84.3%
    Sep 20
    		$-0.19$-0.19+0.00%Beat+73.2%
    Jun 20
    		$-0.51$-0.24-112.50%Miss+34.6%
    Mar 20
    		$-0.41$-0.41+0.00%Beat+59.8%
    Dec 19
    		$-0.51$-0.51+0.00%Beat+53.2%
    Sep 19
    		$-0.71$-0.84+15.48%Beat+34.3%
    Jun 19
    		$-0.78$-1.02+23.53%Beat+56.7%
    Mar 19
    		$-1.02$-1.07+4.67%Beat+83.2%
    Dec 18
    		$-1.09$-1.05-3.81%Miss+74.8%
    Sep 18
    		$-1.08$-1.98+45.45%Beat+87.5%
    Jun 18
    		$-1.80$-1.98+9.09%Beat+81.7%
    Mar 18
    		$-6.06$-5.76-5.21%Miss+68.8%
    Dec 17
    		$-4.32N/A+52.00%Beat+80.7%
    Sep 17
    		$-8.64$-17.28+50.00%Beat+64.6%
    Jun 17
    		$-9.82N/A+57.38%Beat-
    Mar 17
    		$-19.44$-17.28-12.50%Miss-
    Dec 16
    		$-22.44$-23.04+2.60%Beat-
    Sep 16
    		$-24.41$-23.28-4.85%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.66EV/EBITDA-3.66x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-9245.00%
    ROE-94.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.30xQuick Ratio3.30x
    Trading Statistics
    Beta1.44Avg Volume716.21K
    52-Week High$3.3152-Week Low$0.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.95
    SMA 20$0.96
    SMA 50$1.04
    SMA 200$1.74
    EMA 10$0.96
    EMA 20$0.96
    EMA 50$1.07
    EMA 200$1.66

    MACD

    Line: -0.01Signal: -0.03Hist: 0.01

    ADX

    ADX: 18.9+DI: 21.5-DI: 19.3

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down8.0
    PSAR$1.10

    Bollinger Bands

    Upper Band$1.06
    Lower Band$0.86
    %B Position2037%(Upper)
    Band Width0.66

    RSI (14-Day)

    Neutral
    51.5

    Momentum Oscillators

    Stoch %K40.4
    Stoch %D42.9
    Williams %R-51.9
    ROC (10d)9.9%
    Momentum0.09
    CCI (20d)5.8
    MFI (14d)45.5

    Volatility Measures

    ATR (14d)$0.08(7.7%)
    StdDev (20d)0.05
    Hist Vol70.7%(High)

    Volume Flow

    VWAP$0.97
    OBV-57.6M
    AD Line-45.7M
    CMF (20d)-0.047

    Volume Metrics

    Avg Vol (20d)687.8K
    Vol Ratio0.9x
    VWMA (20d)$0.97

    Pivot Points

    R3$1.04
    R2$1.02
    R1$0.98
    Pivot Point$0.96
    S1$0.92
    S2$0.90
    S3$0.86

    Advanced Oscillators

    TSI-5.59
    Ultimate Osc46.5
    KST-23.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$104,000$41,000$243,000$120,000$121,000$109,000$150,000$165,000$163,000$205,000$156,000$141,000
    Cost of Revenue$0$0$223,000$0$0$0$96,000$0$0$0$103,000$0
    Gross Profit$104,000$41,000$243,000$120,000$121,000$109,000$150,000$165,000$163,000$205,000$156,000$141,000
    Operating Expenses$9.72M$12.89M$8.07M$12.09M$14.90M$14.49M$12.72M$12.77M$12.71M$11.14M$10.49M$10.96M
    R&D$5.92M$6.76M$5.08M$8.20M$11.58M$10.48M$9.71M$9.64M$9.49M$8.01M$7.76M$8.02M
    SG&A$3.80M$6.13M$3.00M$3.90M$3.32M$4.01M$3.01M$3.13M$3.21M$3.13M$2.73M$2.94M
    Operating Income$-9,615,000$-12,850,000$-7,827,000$-11,974,000$-14,777,000$-14,382,000$-12,572,000$-12,601,000$-12,545,000$-10,933,000$-10,332,000$-10,820,000
    Interest Income$382,000$506,000$612,000$716,000$835,000$941,000$787,000$741,000$805,000$926,000$1.01M$1.07M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-9,232,000$-12,345,000$-7,216,000$-11,258,000$-13,943,000$-13,434,000$-11,787,000$-11,855,000$-11,778,000$-10,011,000$-9,337,000$-9,731,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,232,000$-12,345,000$-7,216,000$-11,258,000$-13,943,000$-13,434,000$-11,787,000$-11,855,000$-11,778,000$-10,011,000$-9,337,000$-9,731,000
    EBITDA$-9,456,000$-12,723,000$-8,303,000$-12,002,000$-14,850,000$-14,284,000$-12,501,000$-12,517,000$-12,470,000$-10,857,000$-10,447,000$-11,003,000
    EBIT$-9,614,000$-12,851,000$-7,828,000$-11,974,000$-14,778,000$-14,375,000$-12,574,000$-12,596,000$-12,583,000$-10,937,000$-10,345,000$-10,799,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRDF

    News

    William Blair Downgrades Cardiff Oncology(CRDF.US) to Hold Rating

    William Blair has downgraded Cardiff Oncology (CRDF.US) to a Hold rating. This change in rating suggests a revised outlook from the firm regarding the company's stock performance.

    Moomoo•8/21/26•
    Bearish

    Equities Analysts Offer Predictions for CRDF Q3 Earnings

    Zacks Research increased its Q3 2026 EPS estimate for Cardiff Oncology (NASDAQ:CRDF) to a loss of $0.15 per share, with full-year 2026 estimates now at a loss of $0.64 per share. Despite the slight improvement in the Q3 estimate, analyst sentiment has generally weakened, leading to an average "Hold" rating and a $7.50 price target. The company recently reported a Q2 loss of $0.14 per share, missing expectations, and company insiders have recently purchased shares.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C

    This article provides the enterprise value to EBIT forward for Cardiff Oncology, Inc. (DUS:XE7C) on the Dusseldorf Stock Exchange. It's a financial data point for the company, accessible through TradingView's platform, indicating its valuation metric. The content itself is quite sparse, mainly serving as a placeholder for the financial data on the platform.

    TradingView•8/17/26•
    Neutral

    Cardiff Oncology (CRDF) asks investors to double authorized common shares

    Cardiff Oncology (CRDF) is seeking stockholder approval to significantly increase its authorized capital stock, specifically doubling its common stock from 150 million to 300 million shares. This move aims to provide the company with greater flexibility for future financings, strategic transactions, equity incentives, and other corporate purposes, though it acknowledges potential dilution for existing stockholders. The board unanimously recommends voting "FOR" the proposal, which will be decided at a special meeting in October 2026.

    Stock Titan•8/14/26•
    Somewhat-Bearish

    CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING

    William Blair has downgraded its rating for Cardiff Oncology, Inc. to Market Perform. This article from Reuters, republished by Webull, indicates a change in analyst sentiment towards the company. Further details on the reasons for the downgrade would require logging in to the Webull platform.

    Webull•8/13/26•
    Bearish

    Frequently Asked Questions About CRDF

    Does CRDF pay dividends?
    Cardiff Oncology Inc (CRDF) does not currently pay a regular dividend.
    What is CRDF's market cap?
    Cardiff Oncology Inc (CRDF) has a market capitalization of $73.13M with a current stock price of $0.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In